Connor Clark & Lunn Investment Management Ltd. Purchases 21,189 Shares of Johnson & Johnson $JNJ

Key Points

• Connor Clark & Lunn increased its Johnson & Johnson stake by 7.4% in the second quarter, purchasing 21,189 shares for a total holding of 307,423 shares valued at approximately $78.1 million. Institutional investors collectively own 69.55% of JNJ.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $272.83; several firms recently raised their targets to as high as $287. JNJ also exceeded quarterly earnings and revenue expectations.
• Despite strong performance and a 64-year dividend-growth record, valuation and legal risks remain concerns. The stock has gained about 60% over the past year, while executives have sold shares and talc litigation remains unresolved.

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 307,423 shares of the company's stock after buying an additional 21,189 shares during the period. Connor Clark & Lunn Investment Management Ltd.'s holdings in Johnson & Johnson were worth $78,076,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Capital Square LLC lifted its stake in Johnson & Johnson by 1.6% during the 2nd quarter. Capital Square LLC now owns 7,530 shares of the company's stock valued at $1,935,000 after acquiring an additional 117 shares in the last quarter. Mission Financial Group LLC purchased a new position in Johnson & Johnson in the second quarter worth $615,000. Elefante Mark B grew its stake in Johnson & Johnson by 9.8% in the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock valued at $7,285,000 after purchasing an additional 2,563 shares during the period. LM Advisors LLC increased its position in shares of Johnson & Johnson by 309.2% during the 2nd quarter. LM Advisors LLC now owns 9,022 shares of the company's stock valued at $2,291,000 after purchasing an additional 6,817 shares during the last quarter. Finally, First Nebraska Trust Co raised its stake in shares of Johnson & Johnson by 1.2% during the 2nd quarter. First Nebraska Trust Co now owns 67,346 shares of the company's stock worth $17,104,000 after purchasing an additional 802 shares during the period. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. Freedom Capital raised shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. The Goldman Sachs Group restated a "buy" rating and set a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research note on Wednesday, July 15th. Finally, Guggenheim increased their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $272.83.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst sentiment remains supportive. JNJ received an upgrade that helped it reach a new 12-month high, while the broader analyst view is rated “Moderate Buy.” UBS also began coverage, potentially increasing institutional attention. Johnson & Johnson Reaches New 12-Month High Following Analyst Upgrade Johnson & Johnson Receives Average Rating of Moderate Buy
• Positive Sentiment: Johnson & Johnson’s 64-year record of dividend growth remains a key support for income-oriented investors. Strong profitability and the company’s diversified healthcare portfolio help sustain the dividend despite competitive pressure on a major drug. Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect
• Neutral Sentiment: Management will discuss the business at the Deutsche Bank Healthcare Summit on September 17. The event could provide updates on pharmaceuticals, litigation and forward guidance, but it is not itself a change to earnings expectations. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
• Negative Sentiment: Profit-taking and valuation risk are elevated after JNJ gained about 60% over the past year versus roughly 21% for the S&P 500. Analysts question whether the current price already discounts growth above management’s near-term outlook. Was JNJ Stock Rally Actually Its Own? Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
• Negative Sentiment: An executive vice president sold 33,597 shares worth approximately $9.2 million, reducing his holdings by 56.9%. The sale may reinforce short-term concerns about insider conviction, although it does not change JNJ’s fundamentals. SEC insider transaction filing
• Negative Sentiment: An analyst lowered the FY2026 EPS forecast, adding pressure to expectations. Talc litigation also remains unresolved despite a proposed path toward settlement, while the Louisiana verdict continues to focus attention on legal liability and potential costs. Johnson & Johnson dividend and competition analysis

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $275.12 on Friday. Johnson & Johnson has a twelve month low of $173.33 and a twelve month high of $281.07. The stock has a market cap of $663.01 billion, a P/E ratio of 31.88, a PEG ratio of 2.66 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The business's 50-day moving average price is $261.98 and its two-hundred day moving average price is $245.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's dividend payout ratio is currently 62.11%.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 97,569 shares of company stock worth $25,476,044 in the last ninety days. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.